Alzamend Neuro is trading 9.02% higher at $1.45 on October 2; no clear company-specific catalyst has been identified.
- The stock fell 23.99% to $1.31 at the October 1 close; its latest listed press release is dated September 16.
- Broader markets are higher after weaker-than-expected U.S. jobs data, but the rebound cannot be confidently linked to that backdrop. Trading-volume details were not reported, leaving the specific driver unclear.